DE69920496D1 - Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress - Google Patents

Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress

Info

Publication number
DE69920496D1
DE69920496D1 DE69920496T DE69920496T DE69920496D1 DE 69920496 D1 DE69920496 D1 DE 69920496D1 DE 69920496 T DE69920496 T DE 69920496T DE 69920496 T DE69920496 T DE 69920496T DE 69920496 D1 DE69920496 D1 DE 69920496D1
Authority
DE
Germany
Prior art keywords
donor
piperidine
nitrogen oxide
containing nitrogen
derivatives containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920496T
Other languages
English (en)
Other versions
DE69920496T2 (de
Inventor
Erik Emil Aenggard
Abdullah Ibrahim Haj-Yehia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Oxon Medica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxon Medica Inc filed Critical Oxon Medica Inc
Publication of DE69920496D1 publication Critical patent/DE69920496D1/de
Application granted granted Critical
Publication of DE69920496T2 publication Critical patent/DE69920496T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69920496T 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress Expired - Lifetime DE69920496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9801398 1998-01-22
GBGB9801398.0A GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds
PCT/GB1999/000231 WO1999037616A1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress

Publications (2)

Publication Number Publication Date
DE69920496D1 true DE69920496D1 (de) 2004-10-28
DE69920496T2 DE69920496T2 (de) 2005-08-25

Family

ID=10825732

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920496T Expired - Lifetime DE69920496T2 (de) 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress

Country Status (9)

Country Link
US (3) US6448267B1 (de)
EP (1) EP1124801B1 (de)
JP (1) JP2002501049A (de)
AT (1) ATE277012T1 (de)
AU (1) AU4120699A (de)
CA (1) CA2318208C (de)
DE (1) DE69920496T2 (de)
GB (1) GB9801398D0 (de)
WO (1) WO1999037616A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
GB2349385A (en) * 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
KR20010038797A (ko) * 1999-10-27 2001-05-15 김길환 홍국을 이용한 일산화질소 생성제 조성물 및 이를 이용한 약품 조성물
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
YU12703A (sh) * 2000-08-22 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Farmaceutska kombinacija antagonista angiotenzina ii i inhibitora angiotenzin i konvertujućeg enzima
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20020151431A1 (en) * 2001-01-26 2002-10-17 Jeff Thornton Recovery method
WO2002058686A2 (en) * 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
ATE517617T1 (de) * 2001-12-10 2011-08-15 Yansheng Dr Du Behandlung von parkinson erkrankung mit kape
DE60302454T2 (de) * 2002-04-19 2006-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
US20060247216A1 (en) * 2002-10-25 2006-11-02 Haj-Yehia Abdullah I Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
EP1603556A2 (de) * 2003-03-06 2005-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Multifunktionelle verbindungen enthaltend gruppen zur nachahmung von sod zur behandlung von chronisch-entzündlichen darmerkrankungen
EP1732577B1 (de) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topische verabreichung von l-arginin zur verbesserung des aussehens von körper und haut
WO2005102307A2 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
NZ551782A (en) 2004-06-03 2010-03-26 Athlomics Pty Ltd Agents and methods for diagnosing stress
US20070254900A1 (en) * 2004-08-11 2007-11-01 Kassab Ghassan S Treatments for Congestive Heart Failure
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20090062338A1 (en) * 2005-02-02 2009-03-05 Louis Habash Nitroxides for use in treating or preventing cardiovascular disease
US8563581B2 (en) 2005-02-02 2013-10-22 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating predisposed or at risk patients
EP1858525A2 (de) * 2005-02-16 2007-11-28 Nitromed, Inc. Organische stickoxidspendersalze antimikrobieller verbindungen, zusammensetzungen und verwendungsverfahren
CA2597444A1 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
EP1933845A2 (de) 2005-08-25 2008-06-25 Medtronic Vascular, Inc. Stickoxid freisetzende biologisch abbaubare polymere als medizinprodukte und beschichtungen dafür
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
EA200802319A1 (ru) * 2006-05-11 2009-06-30 Белл Хеликоптер Текстрон, Инк. Способ и устройство для ремонта элементов конструкции
US7985594B2 (en) * 2006-05-12 2011-07-26 Massachusetts Institute Of Technology Biradical polarizing agents for dynamic nuclear polarization
WO2007134160A2 (en) * 2006-05-12 2007-11-22 Massachusetts Institute Of Technology Temperature-jump dynamic nuclear polarization
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
JP5191702B2 (ja) * 2006-08-01 2013-05-08 三菱レイヨン株式会社 Ｎ−オキシル化合物、その製造方法および重合防止方法
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US20120245080A1 (en) 2009-04-15 2012-09-27 Bmg Pharma Llc Mineral salt-sulfonic acid compositions and methods of use
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
KR101643797B1 (ko) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 이부프로펜을 함유하는 국소 조성물
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
JP2013518097A (ja) 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP4491225A3 (de) 2010-12-29 2025-03-26 Strategic Science & Technologies, LLC Behandlung von erektiler dysfunktion und anderen indikationen
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
WO2013005216A1 (en) * 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
US8715621B2 (en) 2012-03-15 2014-05-06 Massachusetts Institute Of Technology Radical polarizing agents for dynamic nuclear polarization
WO2013190497A2 (en) * 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
WO2014136059A2 (en) * 2013-03-05 2014-09-12 Radikal Therapeutics Inc. Prodrugs of multifunctional nitroxide derivatives and uses thereof
EP3273956B1 (de) * 2015-03-26 2020-05-06 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Nitroxidradikale zur behandlung von atemwegserkrankungen
AU2021400952A1 (en) 2020-12-15 2023-06-29 Life Technologies Corporation Chemically defined serum albumin substitutes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752812A (en) 1970-02-05 1973-08-14 Pfizer 2-trifluoromethylquinoxalinedi n oxides
US4563446A (en) 1983-07-27 1986-01-07 Takeda Chemical Industries, Ltd. Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
DE3328365A1 (de) * 1983-08-03 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Neue diagnostische mittel
US5352442A (en) 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5890387A (en) 1989-08-24 1999-04-06 Aquaform Inc. Apparatus and method for forming and hydropiercing a tubular frame member
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
DE69412109T2 (de) 1993-10-06 1999-01-21 Nicox S.A., Paris Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
SI0759899T1 (en) 1994-05-10 1999-12-31 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
WO1996039409A1 (en) 1995-06-05 1996-12-12 Nitromed, Inc. Nitrosylated and nitrated superoxide oxidants and reductants
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US6140309A (en) 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5885842A (en) 1996-11-08 1999-03-23 Medinox, Inc. Methods for the detection of nitric oxide in fluid media
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
JP3377731B2 (ja) * 1997-09-29 2003-02-17 三菱重工業株式会社 高性能水素分離膜
WO1999040787A1 (en) 1998-02-13 1999-08-19 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (de) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
ATE276241T1 (de) 1998-11-25 2004-10-15 Yissum Res Dev Co Antioxidationsmittel
JP2002542147A (ja) 1998-12-14 2002-12-10 セレジィ ファーマシューティカルス， インコーポレイテッド 肛門直腸障害の処置のための組成物および方法
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide

Also Published As

Publication number Publication date
US6448267B1 (en) 2002-09-10
US20030069429A1 (en) 2003-04-10
AU4120699A (en) 1999-08-09
WO1999037616A1 (en) 1999-07-29
ATE277012T1 (de) 2004-10-15
US6759430B2 (en) 2004-07-06
GB9801398D0 (en) 1998-03-18
EP1124801A1 (de) 2001-08-22
US20020091266A1 (en) 2002-07-11
CA2318208C (en) 2009-09-29
JP2002501049A (ja) 2002-01-15
CA2318208A1 (en) 1999-07-29
DE69920496T2 (de) 2005-08-25
US6455542B1 (en) 2002-09-24
EP1124801B1 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
DE69920496D1 (de) Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
MY119820A (en) Guanidine mimics as factor xa inhibitors
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
PE74399A1 (es) Combinaciones para diabetes de sulfonilurea - glitazona
UA35574C2 (uk) Похідні заміщеної гетероциклом фенілциклогексанкарбонової кислоти, суміші їх ізомерів або окремі ізомери та їх солі
TR199901765T2 (xx) S�lfomid-metalloproteaz inhibit�rleri
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
BR0112254A (pt) Lìquido para tratamento ácido e processo para tratamento de superfìcies de cobre
DK0722319T3 (da) Anthracyclinonderivater samt deres anvendelse ved amyloidose
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
DE60220997D1 (de) N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält
NO995594L (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
DE59003043D1 (de) Mittel zum Schutz von Pflanzen gegen Krankheiten.
ATE102614T1 (de) Benzo-1,2,3-thiadiazol-derivate und ihre verwendung zum schutz von pflanzen gegen krankheiten.
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
DE69312849D1 (de) Mercapto-acetamid-derivate
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
TR200100476T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
TH35214A (th) ตัวยับยั้งแอสพาร์ทิลโปรทีเอส
TH3364A (th) เฟนนิลเบนโซอิลยูเรีย
TH18189A (th) 5-ไวนิล-และ 5-เอไธนิล-ควิโนโลน- และ-แนพธิริโดน-คาร์บอกซิลิกแอซิด

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

8364 No opposition during term of opposition